1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Sanofi/Regeneron's Libtayo Pivotal Data Shines In Fourth Cancer Type

Phase III Trial In Cervical Cancer Stopped Early Due To Good OS Results

 
• By Sten Stovall

The Sanofi/Regeneron PD-1 inhibitor Libtayo has become the first immunotherapy to demonstrate an improved overall survival in patients with cervical cancer in a Phase III trial.

Cervical Cancer
• Source: Shutterstock

Sanofi and Regeneron Pharmaceuticals, Inc.'s Libtayo (cemiplimab) looks likely to extend its recent run of regulatory approvals as an oncology treatment after the PD-1 inhibitor became the first immunotherapy to demonstrate improved overall survival in patients with cervical cancer.

Positive results from a Phase III trial evaluating Libtayo as a monotherapy for patients whose cervical cancer is recurrent or...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Ireland’s Got Biopharma Talent To Keep Leading The Pack

 
• By Kevin Grogan

The country’s life sciences investment head tells Scrip that it is business as usual for the sector despite the rumblings from across the Atlantic.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.

More from R&D

Immuneering Could Partner Atebimetinib Or Go It Alone After Phase IIa Success

 
• By Alaric DeArment

CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.

Enliven Raises $230m To Fund Scemblix Leukemia Challenger

 
• By Andrew McConaghie

The company believes its drug could eventually displace Novartis’s Scemblix in first-line chronic myeloid leukemia treatment, but for now is preparing for a second-/third-line pivotal study.

Profit-Sharing AI Model Proposed To Boost Korean Drug R&D

 
• By Jung Won Shin

A differentiated profit-sharing model to accelerate the use of AI in drug development using clinical and patient data is being proposed in South Korea, but the idea faces multiple practical challenges